C3 nephritic factors: A changing landscape
Autor*in: |
Levy Erez, Daniella [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2017 |
---|
Schlagwörter: |
membranoproliferative glomerulonephritis |
---|
Umfang: |
3 |
---|
Übergeordnetes Werk: |
Enthalten in: Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward - Papakitsou, I. ELSEVIER, 2022, official publication of the American Academy of Allergy, Asthma and Immunology, Amsterdam [u.a.] |
---|---|
Übergeordnetes Werk: |
volume:140 ; year:2017 ; number:1 ; pages:57-59 ; extent:3 |
Links: |
---|
DOI / URN: |
10.1016/j.jaci.2017.02.018 |
---|
Katalog-ID: |
ELV014719487 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | ELV014719487 | ||
003 | DE-627 | ||
005 | 20230623115322.0 | ||
007 | cr uuu---uuuuu | ||
008 | 180602s2017 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.jaci.2017.02.018 |2 doi | |
028 | 5 | 2 | |a GBVA2017001000003.pica |
035 | |a (DE-627)ELV014719487 | ||
035 | |a (ELSEVIER)S0091-6749(17)30406-2 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | |a 610 | |
082 | 0 | 4 | |a 610 |q DE-600 |
082 | 0 | 4 | |a 610 |q VZ |
084 | |a 44.85 |2 bkl | ||
100 | 1 | |a Levy Erez, Daniella |e verfasserin |4 aut | |
245 | 1 | 0 | |a C3 nephritic factors: A changing landscape |
264 | 1 | |c 2017 | |
300 | |a 3 | ||
336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
337 | |a nicht spezifiziert |b z |2 rdamedia | ||
338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
650 | 7 | |a C3 nephritic factor |2 Elsevier | |
650 | 7 | |a membranoproliferative glomerulonephritis |2 Elsevier | |
650 | 7 | |a C3 glomerulopathy |2 Elsevier | |
650 | 7 | |a alternative complement activation |2 Elsevier | |
650 | 7 | |a eculizumab |2 Elsevier | |
650 | 7 | |a partial lipodystrophy |2 Elsevier | |
650 | 7 | |a dense-deposit disease |2 Elsevier | |
700 | 1 | |a Meyers, Kevin E. |4 oth | |
700 | 1 | |a Sullivan, Kathleen E. |4 oth | |
773 | 0 | 8 | |i Enthalten in |n Elsevier |a Papakitsou, I. ELSEVIER |t Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward |d 2022 |d official publication of the American Academy of Allergy, Asthma and Immunology |g Amsterdam [u.a.] |w (DE-627)ELV000021164 |
773 | 1 | 8 | |g volume:140 |g year:2017 |g number:1 |g pages:57-59 |g extent:3 |
856 | 4 | 0 | |u https://doi.org/10.1016/j.jaci.2017.02.018 |3 Volltext |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ELV | ||
912 | |a SYSFLAG_U | ||
912 | |a SSG-OLC-PHA | ||
936 | b | k | |a 44.85 |j Kardiologie |j Angiologie |q VZ |
951 | |a AR | ||
952 | |d 140 |j 2017 |e 1 |h 57-59 |g 3 | ||
953 | |2 045F |a 610 |
author_variant |
e d l ed edl |
---|---|
matchkey_str |
levyerezdaniellameyerskevinesullivankath:2017----:3ehiifcoscagn |
hierarchy_sort_str |
2017 |
bklnumber |
44.85 |
publishDate |
2017 |
allfields |
10.1016/j.jaci.2017.02.018 doi GBVA2017001000003.pica (DE-627)ELV014719487 (ELSEVIER)S0091-6749(17)30406-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.85 bkl Levy Erez, Daniella verfasserin aut C3 nephritic factors: A changing landscape 2017 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier C3 nephritic factor Elsevier membranoproliferative glomerulonephritis Elsevier C3 glomerulopathy Elsevier alternative complement activation Elsevier eculizumab Elsevier partial lipodystrophy Elsevier dense-deposit disease Elsevier Meyers, Kevin E. oth Sullivan, Kathleen E. oth Enthalten in Elsevier Papakitsou, I. ELSEVIER Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward 2022 official publication of the American Academy of Allergy, Asthma and Immunology Amsterdam [u.a.] (DE-627)ELV000021164 volume:140 year:2017 number:1 pages:57-59 extent:3 https://doi.org/10.1016/j.jaci.2017.02.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.85 Kardiologie Angiologie VZ AR 140 2017 1 57-59 3 045F 610 |
spelling |
10.1016/j.jaci.2017.02.018 doi GBVA2017001000003.pica (DE-627)ELV014719487 (ELSEVIER)S0091-6749(17)30406-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.85 bkl Levy Erez, Daniella verfasserin aut C3 nephritic factors: A changing landscape 2017 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier C3 nephritic factor Elsevier membranoproliferative glomerulonephritis Elsevier C3 glomerulopathy Elsevier alternative complement activation Elsevier eculizumab Elsevier partial lipodystrophy Elsevier dense-deposit disease Elsevier Meyers, Kevin E. oth Sullivan, Kathleen E. oth Enthalten in Elsevier Papakitsou, I. ELSEVIER Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward 2022 official publication of the American Academy of Allergy, Asthma and Immunology Amsterdam [u.a.] (DE-627)ELV000021164 volume:140 year:2017 number:1 pages:57-59 extent:3 https://doi.org/10.1016/j.jaci.2017.02.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.85 Kardiologie Angiologie VZ AR 140 2017 1 57-59 3 045F 610 |
allfields_unstemmed |
10.1016/j.jaci.2017.02.018 doi GBVA2017001000003.pica (DE-627)ELV014719487 (ELSEVIER)S0091-6749(17)30406-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.85 bkl Levy Erez, Daniella verfasserin aut C3 nephritic factors: A changing landscape 2017 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier C3 nephritic factor Elsevier membranoproliferative glomerulonephritis Elsevier C3 glomerulopathy Elsevier alternative complement activation Elsevier eculizumab Elsevier partial lipodystrophy Elsevier dense-deposit disease Elsevier Meyers, Kevin E. oth Sullivan, Kathleen E. oth Enthalten in Elsevier Papakitsou, I. ELSEVIER Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward 2022 official publication of the American Academy of Allergy, Asthma and Immunology Amsterdam [u.a.] (DE-627)ELV000021164 volume:140 year:2017 number:1 pages:57-59 extent:3 https://doi.org/10.1016/j.jaci.2017.02.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.85 Kardiologie Angiologie VZ AR 140 2017 1 57-59 3 045F 610 |
allfieldsGer |
10.1016/j.jaci.2017.02.018 doi GBVA2017001000003.pica (DE-627)ELV014719487 (ELSEVIER)S0091-6749(17)30406-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.85 bkl Levy Erez, Daniella verfasserin aut C3 nephritic factors: A changing landscape 2017 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier C3 nephritic factor Elsevier membranoproliferative glomerulonephritis Elsevier C3 glomerulopathy Elsevier alternative complement activation Elsevier eculizumab Elsevier partial lipodystrophy Elsevier dense-deposit disease Elsevier Meyers, Kevin E. oth Sullivan, Kathleen E. oth Enthalten in Elsevier Papakitsou, I. ELSEVIER Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward 2022 official publication of the American Academy of Allergy, Asthma and Immunology Amsterdam [u.a.] (DE-627)ELV000021164 volume:140 year:2017 number:1 pages:57-59 extent:3 https://doi.org/10.1016/j.jaci.2017.02.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.85 Kardiologie Angiologie VZ AR 140 2017 1 57-59 3 045F 610 |
allfieldsSound |
10.1016/j.jaci.2017.02.018 doi GBVA2017001000003.pica (DE-627)ELV014719487 (ELSEVIER)S0091-6749(17)30406-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.85 bkl Levy Erez, Daniella verfasserin aut C3 nephritic factors: A changing landscape 2017 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier C3 nephritic factor Elsevier membranoproliferative glomerulonephritis Elsevier C3 glomerulopathy Elsevier alternative complement activation Elsevier eculizumab Elsevier partial lipodystrophy Elsevier dense-deposit disease Elsevier Meyers, Kevin E. oth Sullivan, Kathleen E. oth Enthalten in Elsevier Papakitsou, I. ELSEVIER Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward 2022 official publication of the American Academy of Allergy, Asthma and Immunology Amsterdam [u.a.] (DE-627)ELV000021164 volume:140 year:2017 number:1 pages:57-59 extent:3 https://doi.org/10.1016/j.jaci.2017.02.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.85 Kardiologie Angiologie VZ AR 140 2017 1 57-59 3 045F 610 |
language |
English |
source |
Enthalten in Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward Amsterdam [u.a.] volume:140 year:2017 number:1 pages:57-59 extent:3 |
sourceStr |
Enthalten in Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward Amsterdam [u.a.] volume:140 year:2017 number:1 pages:57-59 extent:3 |
format_phy_str_mv |
Article |
bklname |
Kardiologie Angiologie |
institution |
findex.gbv.de |
topic_facet |
C3 nephritic factor membranoproliferative glomerulonephritis C3 glomerulopathy alternative complement activation eculizumab partial lipodystrophy dense-deposit disease |
dewey-raw |
610 |
isfreeaccess_bool |
false |
container_title |
Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward |
authorswithroles_txt_mv |
Levy Erez, Daniella @@aut@@ Meyers, Kevin E. @@oth@@ Sullivan, Kathleen E. @@oth@@ |
publishDateDaySort_date |
2017-01-01T00:00:00Z |
hierarchy_top_id |
ELV000021164 |
dewey-sort |
3610 |
id |
ELV014719487 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV014719487</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623115322.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jaci.2017.02.018</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017001000003.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV014719487</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0091-6749(17)30406-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.85</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Levy Erez, Daniella</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">C3 nephritic factors: A changing landscape</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">3</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">C3 nephritic factor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">membranoproliferative glomerulonephritis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">C3 glomerulopathy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">alternative complement activation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">eculizumab</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">partial lipodystrophy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">dense-deposit disease</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Meyers, Kevin E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sullivan, Kathleen E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Papakitsou, I. ELSEVIER</subfield><subfield code="t">Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward</subfield><subfield code="d">2022</subfield><subfield code="d">official publication of the American Academy of Allergy, Asthma and Immunology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000021164</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:140</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:57-59</subfield><subfield code="g">extent:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jaci.2017.02.018</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.85</subfield><subfield code="j">Kardiologie</subfield><subfield code="j">Angiologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">140</subfield><subfield code="j">2017</subfield><subfield code="e">1</subfield><subfield code="h">57-59</subfield><subfield code="g">3</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
author |
Levy Erez, Daniella |
spellingShingle |
Levy Erez, Daniella ddc 610 bkl 44.85 Elsevier C3 nephritic factor Elsevier membranoproliferative glomerulonephritis Elsevier C3 glomerulopathy Elsevier alternative complement activation Elsevier eculizumab Elsevier partial lipodystrophy Elsevier dense-deposit disease C3 nephritic factors: A changing landscape |
authorStr |
Levy Erez, Daniella |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000021164 |
format |
electronic Article |
dewey-ones |
610 - Medicine & health |
delete_txt_mv |
keep |
author_role |
aut |
collection |
elsevier |
remote_str |
true |
illustrated |
Not Illustrated |
topic_title |
610 610 DE-600 610 VZ 44.85 bkl C3 nephritic factors: A changing landscape C3 nephritic factor Elsevier membranoproliferative glomerulonephritis Elsevier C3 glomerulopathy Elsevier alternative complement activation Elsevier eculizumab Elsevier partial lipodystrophy Elsevier dense-deposit disease Elsevier |
topic |
ddc 610 bkl 44.85 Elsevier C3 nephritic factor Elsevier membranoproliferative glomerulonephritis Elsevier C3 glomerulopathy Elsevier alternative complement activation Elsevier eculizumab Elsevier partial lipodystrophy Elsevier dense-deposit disease |
topic_unstemmed |
ddc 610 bkl 44.85 Elsevier C3 nephritic factor Elsevier membranoproliferative glomerulonephritis Elsevier C3 glomerulopathy Elsevier alternative complement activation Elsevier eculizumab Elsevier partial lipodystrophy Elsevier dense-deposit disease |
topic_browse |
ddc 610 bkl 44.85 Elsevier C3 nephritic factor Elsevier membranoproliferative glomerulonephritis Elsevier C3 glomerulopathy Elsevier alternative complement activation Elsevier eculizumab Elsevier partial lipodystrophy Elsevier dense-deposit disease |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
zu |
author2_variant |
k e m ke kem k e s ke kes |
hierarchy_parent_title |
Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward |
hierarchy_parent_id |
ELV000021164 |
dewey-tens |
610 - Medicine & health |
hierarchy_top_title |
Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)ELV000021164 |
title |
C3 nephritic factors: A changing landscape |
ctrlnum |
(DE-627)ELV014719487 (ELSEVIER)S0091-6749(17)30406-2 |
title_full |
C3 nephritic factors: A changing landscape |
author_sort |
Levy Erez, Daniella |
journal |
Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward |
journalStr |
Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward |
lang_code |
eng |
isOA_bool |
false |
dewey-hundreds |
600 - Technology |
recordtype |
marc |
publishDateSort |
2017 |
contenttype_str_mv |
zzz |
container_start_page |
57 |
author_browse |
Levy Erez, Daniella |
container_volume |
140 |
physical |
3 |
class |
610 610 DE-600 610 VZ 44.85 bkl |
format_se |
Elektronische Aufsätze |
author-letter |
Levy Erez, Daniella |
doi_str_mv |
10.1016/j.jaci.2017.02.018 |
dewey-full |
610 |
title_sort |
c3 nephritic factors: a changing landscape |
title_auth |
C3 nephritic factors: A changing landscape |
collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
container_issue |
1 |
title_short |
C3 nephritic factors: A changing landscape |
url |
https://doi.org/10.1016/j.jaci.2017.02.018 |
remote_bool |
true |
author2 |
Meyers, Kevin E. Sullivan, Kathleen E. |
author2Str |
Meyers, Kevin E. Sullivan, Kathleen E. |
ppnlink |
ELV000021164 |
mediatype_str_mv |
z |
isOA_txt |
false |
hochschulschrift_bool |
false |
author2_role |
oth oth |
doi_str |
10.1016/j.jaci.2017.02.018 |
up_date |
2024-07-06T22:16:14.202Z |
_version_ |
1803869669769084928 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV014719487</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623115322.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jaci.2017.02.018</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017001000003.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV014719487</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0091-6749(17)30406-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.85</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Levy Erez, Daniella</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">C3 nephritic factors: A changing landscape</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">3</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">C3 nephritic factor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">membranoproliferative glomerulonephritis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">C3 glomerulopathy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">alternative complement activation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">eculizumab</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">partial lipodystrophy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">dense-deposit disease</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Meyers, Kevin E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sullivan, Kathleen E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Papakitsou, I. ELSEVIER</subfield><subfield code="t">Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward</subfield><subfield code="d">2022</subfield><subfield code="d">official publication of the American Academy of Allergy, Asthma and Immunology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000021164</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:140</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:57-59</subfield><subfield code="g">extent:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jaci.2017.02.018</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.85</subfield><subfield code="j">Kardiologie</subfield><subfield code="j">Angiologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">140</subfield><subfield code="j">2017</subfield><subfield code="e">1</subfield><subfield code="h">57-59</subfield><subfield code="g">3</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
score |
7.4003916 |